HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 278, Issue 12, 10195-10200, March 21, 2003

This Article Full Text Full Text (PDF) All Versions of this Article: 278/12/10195    most recent M212147200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by López de Maturana, R. Articles by Donnelly, D. Search for Related Content PubMed PubMed Citation Articles by López de Maturana, R. Articles by Donnelly, D. Social Bookmarking                      What's this?

The Isolated N-terminal Domain of the Glucagon-like Peptide-1 (GLP-1) Receptor Binds Exendin Peptides with Much Higher Affinity than GLP-1^*

Rakel López de Maturana, Angela Willshaw, Antje Kuntzsch^§, Rainer Rudolph^§, and Dan Donnelly^¶

From the  School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom and the ^§ Institut für Biotechnologie der Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Strasse 3, D-06120 Halle, Germany

Two fragments of the receptor for glucagon-like peptide-1 (GLP-1), each containing the N-terminal domain, were expressed and characterized in either bacterial or mammalian cells. The first fragment, rNT-TM1, included the N-terminal domain and first transmembrane helix and was stably expressed in the membrane of human embryonic kidney 293 cells. The second, 6H-rNT, consisted of only the N-terminal domain of the receptor fused with a polyhistidine tag at its N terminus. The latter fragment was expressed in Escherichia coli in the form of inclusion bodies from which the protein was subsequently purified and refolded in vitro. Although both receptor fragments displayed negligible ¹²⁵I-labeled GLP-1(7-36)amide-specific binding, they both displayed high affinity for the radiolabeled peptide antagonist ¹²⁵I-exendin-4(9-39). Competition binding studies demonstrated that the N-terminal domain of the GLP-1 receptor maintains high affinity for the agonist exendin-4 as well as the antagonists exendin-4(3-39) and exendin-4(9-39) whereas, in contrast, GLP-1 affinity was greatly reduced. This study shows that although the exendin antagonists are not dependent upon the extracellular loops and transmembrane helices for maintaining their normal high affinity binding, the endogenous agonist GLP-1 requires regions outside of the N-terminal domain. Hence, distinct structural features in exendin-4, between residues 9 and 39, provide additional affinity for the N-terminal domain of the receptor. These data are consistent with a model for the binding of peptide ligands to the GLP-1 receptor in which the central and C-terminal regions of the peptides bind to the N terminus of the receptor, whereas the N-terminal residues of peptide agonists interact with the extracellular loops and transmembrane helices.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Dong, F. Gao, D. I. Pinon, and L. J. Miller Insights into the Structural Basis of Endogenous Agonist Activation of Family B G Protein-Coupled Receptors Mol. Endocrinol., June 1, 2008; 22(6): 1489 - 1499. [Abstract] [Full Text] [PDF]

				S. Runge, H. Thogersen, K. Madsen, J. Lau, and R. Rudolph Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain J. Biol. Chem., April 25, 2008; 283(17): 11340 - 11347. [Abstract] [Full Text] [PDF]

				M. H. Perrin, C. R. R. Grace, M. R. DiGruccio, W. H. Fischer, S. K. Maji, J. P. Cantle, S. Smith, G. Manning, W. W. Vale, and R. Riek Distinct Structural and Functional Roles of Conserved Residues in the First Extracellular Domain of Receptors for Corticotropin-releasing Factor and Related G-protein-coupled Receptors J. Biol. Chem., December 28, 2007; 282(52): 37529 - 37536. [Abstract] [Full Text] [PDF]

				C. Sun, D. Song, R. A. Davis-Taber, L. W. Barrett, V. E. Scott, P. L. Richardson, A. Pereda-Lopez, M. E. Uchic, L. R. Solomon, M. R. Lake, et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS PNAS, May 8, 2007; 104(19): 7875 - 7880. [Abstract] [Full Text] [PDF]

				M. Beinborn Class B GPCRs: A Hidden Agonist Within? Mol. Pharmacol., July 1, 2006; 70(1): 1 - 4. [Abstract] [Full Text] [PDF]

				R. Jorgensen, L. Martini, T. W. Schwartz, and C. E. Elling Characterization of Glucagon-Like Peptide-1 Receptor {beta}-Arrestin 2 Interaction: A High-Affinity Receptor Phenotype Mol. Endocrinol., March 1, 2005; 19(3): 812 - 823. [Abstract] [Full Text] [PDF]

				S. Runge, C. Gram, H. Brauner-Osborne, K. Madsen, L. B. Knudsen, and B. S. Wulff Three Distinct Epitopes on the Extracellular Face of the Glucagon Receptor Determine Specificity for the Glucagon Amino Terminus J. Biol. Chem., July 18, 2003; 278(30): 28005 - 28010. [Abstract] [Full Text] [PDF]